Marco Pugliese co-founded Neurotec Pharma on 2006 aiming to develop a treatment for CNS diseases, specially focusing on inflammation and neurodegeneration. From 2008 to 2014 worked as CEO, achieving the main goal of carrying a multi-centre and international Phase II research with 110 RR-Multiple Sclerosis patients. From 2014 to 2015 worked as Innovation and Technology Manager at Vall d’Hebron Research Insitute (VHIR).
From 2015 to 2019 he has been the director of the health Spanish node at EIT Health (European Institue of Technolgy). Since 2007 he is Associate Profesor of Molecular Biochemistry of the Medicine Faculty of the University of Barcelona.
Dr. Pugliese has 7 patents related to the treatment development of CNS diseases, and he is author of 25 international papers in Neuroscience field.
Graduate in Veterinary in 1994 by the University of Perugia (Italy). PhD in Neuroscience by the University of Barcelona on 2005 with a research based on the cognitive disfunction of domestic dogs and its usefulness as an alternative of Alzheimer. In 2005 won a prize by the Spanish Royal Academy of Veterinary Science with a research on selective neurodegeneration of the central neural system of the dog.